ロード中...
Risk of iron overload with chronic indiscriminate use of intravenous iron products in ESRD and IBD populations
The routine use of recombinant erythropoiesis-stimulating agents (ESA) over the past three decades has enabled the partial correction of anaemia in most patients with end-stage renal disease (ESRD). Since ESA use frequently leads to iron deficiency, almost all ESA-treated haemodialysis patients worl...
保存先:
| 出版年: | Heliyon |
|---|---|
| 主要な著者: | , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Elsevier
2019
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6627982/ https://ncbi.nlm.nih.gov/pubmed/31338466 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.heliyon.2019.e02045 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|